Equity

Total Equity

Eli Lilly Total Equity increased by 17.6% to $31.20B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 97.9%, from $15.76B to $31.20B. Over 5 years (FY 2020 to FY 2025), Total Equity shows an upward trend with a 36.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalHigher is better
VolatilityStable
First reportedQ4 2012
Last reportedQ1 2026Apr 30, 2026

How to read this metric

An increase generally signals growth in retained earnings or capital injections, while a decrease may indicate share buybacks, dividend payments, or net losses.

Detailed definition

This represents the residual interest in the assets of the entity after deducting all its liabilities. It reflects the n...

Peer comparison

Standard across all public companies; peers in the medical device and diagnostics sector typically maintain high equity levels to support R&D and M&A.

Metric ID: total_stockholders_equity

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$6.44B$7.76B$8.98B$9.33B$8.54B$10.07B$10.65B$11.19B$11.06B$11.22B$10.77B$12.81B$13.56B$14.24B$14.27B$15.76B$18.27B$23.79B$26.54B$31.20B
QoQ Change+20.4%+15.8%+3.9%-8.4%+17.9%+5.8%+5.1%-1.1%+1.4%-4.0%+18.9%+5.9%+5.0%+0.2%+10.5%+15.9%+30.2%+11.5%+17.6%
YoY Change+32.6%+29.8%+18.6%+19.9%+29.5%+11.4%+1.1%+14.5%+22.6%+26.9%+32.5%+23.0%+34.7%+67.1%+85.9%+97.9%
Range$6.44B$31.20B
CAGR+39.4%
Avg YoY Growth+34.3%
Median YoY Growth+28.2%
Current Streak9 quarters growth

Frequently Asked Questions

What is Eli Lilly's total equity?
Eli Lilly (LLY) reported total equity of $31.20B in Q1 2026.
How has Eli Lilly's total equity changed year-over-year?
Eli Lilly's total equity increased by 97.9% year-over-year, from $15.76B to $31.20B.
What is the long-term trend for Eli Lilly's total equity?
Over 5 years (2020 to 2025), Eli Lilly's total equity has grown at a 36.3% compound annual growth rate (CAGR), from $5.64B to $26.54B.
What does total equity mean?
The total value of the company that belongs to the shareholders after all debts are paid.